Anrukinzumab
Monoclonal antibody for the treatment of asthma
| Anrukinzumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Anrukinzumab is a monoclonal antibody that was developed for the treatment of asthma. It is a humanized antibody that targets the interleukin-13 (IL-13) cytokine, which plays a key role in the inflammatory process associated with asthma.
Mechanism of Action[edit | edit source]
Anrukinzumab works by binding to IL-13, a cytokine involved in the immune system's response to allergens. IL-13 is known to contribute to the pathophysiology of asthma by promoting inflammation, mucus production, and airway hyperresponsiveness. By inhibiting IL-13, anrukinzumab reduces these effects, potentially alleviating symptoms in patients with asthma.
Development and Clinical Trials[edit | edit source]
Anrukinzumab was initially developed by MedImmune, a subsidiary of AstraZeneca. The drug underwent several clinical trials to evaluate its safety and efficacy in treating asthma. However, the development of anrukinzumab was eventually discontinued.
During its clinical evaluation, anrukinzumab was administered to patients with moderate to severe asthma to assess its impact on lung function and asthma control. The trials aimed to determine the optimal dosing regimen and to identify any potential side effects associated with the treatment.
Potential Applications[edit | edit source]
While anrukinzumab was primarily investigated for asthma, the mechanism of targeting IL-13 suggests potential applications in other allergic and inflammatory diseases. IL-13 is implicated in conditions such as atopic dermatitis and chronic rhinosinusitis with nasal polyps, making it a target of interest for various therapeutic interventions.
Discontinuation[edit | edit source]
Despite the promising mechanism of action, the development of anrukinzumab was halted. The reasons for discontinuation could include insufficient efficacy in clinical trials, safety concerns, or strategic business decisions by the developing company.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
